



Investor Presentation

June 2023



Disclaimer

The following presentation, including a hard copy of these slides/the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by Biodexa Pharmaceuticals PLC (the "Company").

The Presentation does not constitute or form part of an offer or invitation to issue or sell, or the solicitation of an offer to subscribe or purchase, any securities of the Company, nor shall it or any part of it, nor the fact of its distribution, form the basis of, or be relied on in connection with, any contract commitment or investment decision in relation thereto. This Presentation and the information contained herein are not an offer of securities for sale and are not for publication or distribution in the United States or to any US person (within the meaning of Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act"), or in Canada, Australia, South Africa or Japan or any jurisdiction where such offer or distribution is unlawful. Any failure to comply with this restriction may constitute a violation of United States securities laws.

Persons in possession of this Presentation are required to inform themselves about and to observe any such restrictions on distribution. No action has been taken or will be taken in any jurisdiction by the Company that would permit the possession or distribution of any documents or any amendment or supplement thereto (including but not limited to this Presentation) in any country or jurisdiction where specific action for that purpose is required.

This Presentation does not constitute an offer or solicitation to purchase or subscribe for securities in the United States. The securities of the Company may not be offered or sold in the United States or to any US person unless the securities are registered under the Securities Act or an exemption therefrom is available. Neither the U.S. Securities and Exchange Commission ("SEC"), nor any other United States authority, has approved this Presentation.

The Presentation is provided for general information only and does not purport to contain all the information relating to the Company. The information in the Presentation is provided as at the date of the Presentation (unless stated otherwise) and is subject to updating, completion, revision and further verification. In furnishing the Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update the Presentation or to correct any inaccuracies in, or omissions from the Presentation which may become apparent. No reliance may be placed for any purpose whatsoever on the information or opinions contained or expressed in the Presentation or on the accuracy, completeness or fairness of such information and opinions.

Nothing in the Presentation is, or should be relied on as, a promise or representation as to the future. This Presentation contains certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances, not historical facts and are sometimes identified by the words "believes", "expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in this Presentation (including assumptions, opinions and views of the Company or opinions cited from third party sources) are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. None of the Company or any officers, directors, or employees of the Company provides any assurance that the assumptions underlying such forward-looking statements are free from errors, nor does any of them accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecasted developments described herein. No representations or warranties of any kind are made by any person as to the accuracy of such statements, estimates or projections, or that any of the events expressed or implied in any such statements, estimates or projections will actually occur. The Company is not under any obligation, and expressly disclaims any intention, to update or revise any such statements, estimates or projections. No statement in the Presentation is intended as a profit forecast or a profit estimate.

AN INVESTMENT IN THE COMPANY INVOLVES RISK. SEVERAL FACTORS COULD CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS THAT MAY BE PREDICTED OR IMPLIED BY STATEMENTS AND INFORMATION IN THIS PRESENTATION. SHOULD ONE OR MORE OF THESE RISKS OR UNCERTAINTIES MATERIALIZE, OR SHOULD UNDERLYING ASSUMPTIONS PROVE INCORRECT, THE ACTUAL RESULTS OF THE COMPANY MAY VARY MATERIALLY FROM THOSE FORECASTED IN THE PRESENTATION.

OTHER FACTORS THAT COULD ADVERSELY AFFECT THE COMPANY'S BUSINESS AND PROSPECTS ARE DESCRIBED IN THE FILINGS MADE BY THE COMPANY WITH THE SEC, INCLUDING ITS MOST RECENT ANNUAL REPORT ON FORM 20-F.



Biodexa Pharmaceuticals Overview

Clinical stage biopharmaceutical company

Currently focussed on treatments for rare primary and metastatic cancers of the brain

Publicly traded

NASDAQ: BDRX

Headquartered in UK

About 15 employees based out of facilities in Cardiff, South Wales



Our Team



Stephen Stamp
CEO/CFO



Dmitry Zamoryakhin
Chief Scientific Officer



Steve Ellul
VP Business Development



Dan Palmer
VP Technology




Fiona Sharp
Group Financial Controller



Development Pipeline

	Indication	Preclinical	Phase 1	Phase2	Phase3
MTX110 (panobinostat)	Diffuse Midline Glioma				
	Glioblastoma				
	Medulloblastoma				
MTD217 (Panobinostat + OXPPOS inhibitor)	Leptomeningeal Disease				



Company Strategy

BUILD

Acquire portfolio of assets focussed on the oncology / rare orphan space

Target assets in late pre-clinical / early clinical stage

DEVELOP

Validate assets through proof of principle studies in humans

Progress through to completion of phase 1/2 studies

PARTNER


License out to pharma partners

Partners to sponsor phase 3 programme and commercialise







MTX110
Intratumoral Panobinostat
for
Treatment for Brain Cancers



Why Panobinostat?


- In a screen of 83 drugs panobinostat was among the most effective agents¹
- Convection-enhanced delivery (CED) to directly infuse panobinostat into the pons of a DMG orthotopic xenograft model showed:
 - A marked effect on the rate of DMG xenograft growth¹
 - Significantly prolonged survival compared to controls¹



1. Grasso et al; Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma; at Med. 2015 June ; 21(6): 555–559. doi:10.1038/nm.3855.

MTX110 Product Concept


Optimised Therapeutic Dose with Minimal Potential for Systemic Exposure



MTX110

Diffuse Midline Glioma (DMG)

- **Significant unmet medical need**
 - About 300 children diagnosed in the US pa¹, over 1,100 worldwide²
 - Median survival of approximately 10 months [ref]
 - Resection not possible, no effective treatment³
- **Phase I programme:**
 - '201 study (UCSF) n=7 showed
 - '203 study (Columbia) n=9 recruiting final patient
- **Phase II planning in progress**




Gd-MRI showing CED targeted delivery of MTX110 to brainstem tumour

1. [Dana-Farber Cancer Institute](#) 2. [DIPG International Registry](#) 3. [DIPG.org](#)


MTX110

Diffuse Midline Glioma (DMG) – Clinical Data

Overall survival for all patients



Number at risk



The median overall survival (OS) for cohort was 26.1 months (95% confidence interval)

Median survival based on a cohort of 316 cases was 10.0 months¹


1. Jansen et al, 2015. Neuro-Oncology 17(1):160-166



MTX110

Glioblastoma (GBM) Background

- **Most common and aggressive form of brain cancer in adults**
- **Survival with standard of care treatment ranges from approximately 13 to 30 months depending on MGMT methylation.**
 - Standard of care: resection, radiation, limited drug options
 - Near 100% recurrence
- **More than 13,000 GBM diagnoses pa in US¹**
 - Global incidence: 3 -4 per 100,000²
- **Global GBM treatment market valued at US\$ 2.14 billion in 2023, expected to grow at 8.8% pa through 2028⁴**



1. [National Brain Tumor Society](#) 2. Epidemiology of Glioblastoma Multiforme—Literature Review (MDPI) 3. [Grand View Research](#)

MTX110

Glioblastoma (GBM)

- **Problem:**

- Many drug failures due to poor BBB penetration

- **Potential Solution:**

- MTX110 is delivered intra-tumorally at high doses via CED, by-passing BBB
- Compelling mechanism and preclinical evidence of efficacy in GBM models
- Encouraging data from DIPG studies

- **Phase I (MAGIC – G1 study) recruiting:**

- Two centers: Duke and MD Anderson Baptist
- Open label, dose escalation
- Two cohorts: MTX110, then MTX110 plus lomustine
- First data readout expected Q3 2023




Figure 1. Tumour volume data from IDH1 mutated tumour bearing mice resulted in a significant reduction in tumour growth compared to control.




Figure 2. MTX110 is highly potent at therapeutically feasible concentrations in four patient-derived GBM cell lines

MTX110

Medulloblastoma Background

- **Cancerous brain tumour that starts in the cerebellum in the lower back part of the brain**
- **Most common cancerous brain tumour in children**
 - Accounts for 20% of childhood brain tumours
- **5-year relative survival rate for children age 14 and younger of 72%**
- **About 500 children in the United States¹ and 650 in Europe² are diagnosed with medulloblastoma each year**



1. Cancer.Net Epidemiology of Glioblastoma Multiforme–Literature Review (MDPI) 2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773789/>



MTD217

Leptomeningeal Disease (LMD) Background

- **Cancer in the cerebrospinal fluid and leptomeninges caused by metastases**
 - Most commonly arises from breast and lung cancers
- **Approximately 5% of people who have cancer develop¹ LMD**
- **No effective treatments currently exist for LMD**
- **With treatment, survival is just three to six months after diagnosis¹**



1. <https://my.clevelandclinic.org/health/diseases/22737-leptomeningeal-disease>



Corporate Milestones



MTX 110 Milestones - 2023

